ZZZhuo Zhang

Zhuo Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhuo Zhang has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Amino acid-improved bovine serum albumin microbubbles for the focused ultrasound-mediated drug delivery and attenuation of α-synuclein fibrils

    by Zhuo Zhang, Wei Hu, Jiaxi Xu, Zeyu He, Fan Zhang, Pan Liang, Zhiming Wang, Zhen Fan

    The misfolded and aggregation of α­syn are considered one of the culprits of Parkinson’s disease (PD), yet existing clinical therapies are still limited in the efficacy. Herein, the strategy of the microbubbles combined with focused ultrasound was employed to open the blood brain barrier for fast drug delivery into the brain. Specifically, the bovine serum albumin microbubbles (MBs) with excellent stability were produced through improved preparation method as well as introduction of L-glutamic acid. The stability of concentration and diameter were increased by 4.3 and 2.0 times than traditional method, respectively. Meanwhile, quinones, dipeptide HY and fluorescence dye Cy7 were conjugated together (DNHY-Cy7) for the interference of α-syn aggregation and imaging. The results indicate that DNHY was able to attenuate α-syn fibrils, α-syn fibrillization and the amount of α-syn fibrils are gradually reduced by 59.3% and 69.4%, respectively, which additionally reducing α-syn fibrils induced ROS, mitochondrial and membrane damage. Importantly, the MBs carried with DNHY-Cy7 (MBs@DNHY-Cy7) were able to open the blood brain barrier with the irradiation of focused ultrasound within 2 min, thus the delivery and accumulation of DNHY-Cy7 into the brain were achieved, which may present a promising strategy for α-syn related PD therapy.

  • Open Access

    A Metal-Peptide Framework as a Nanozyme for the Attenuation of Amyloid-β Aggregation and Reactive Oxygen Species

    by Zhuo Zhang, Mingchen Lv, Jiaxi Xu, Yaping Liu, Jinlong Qin, Zhen Fan, Jianzhong Du

    Alzheimer’s disease (AD) is an irreversible neurodegenerative disease characterized by abnormal performance in memory, cognition, and language, and it imposes a heavy economic burden worldwide. Amyloidosis and oxidative stress are highly associated with AD progression, yet limited clinical drugs are available at present. Nanozymes exhibit diverse enzyme-mimetic activities and have attracted widespread attention as a promising alternative candidate for scavenging reactive oxygen species to maintain the oxidation–antioxidation balance in cells. Neurotoxic amyloid-β (Aβ) aggregation is also a critical event in AD pathology. The development of dual-targeting nanomaterials with antiamyloidosis ability and enzyme-mimicking activity is expected to be a promising strategy for the treatment of amyloidosis and reactive oxygen species-mediated AD progression. Here, bimetallic-peptide framework nanozymes (CuZn-PEP NZs) with amyloid-β (Aβ) attenuating ability, multiple enzyme-mimicking properties, and broad-spectrum reactive oxygen species scavenging capacity were endowed to inhibit Aβ fibrillization, disaggregate Aβ fibrils, and scavenge Aβ fibril-induced reactive oxygen species. An obvious inhibitory effect on Aβ fibrillization and a disaggregation effect on Aβ fibrils were observed after treatment with CuZn-PEP NZs. Meanwhile, the cytotoxicity of Aβ fibrils toward PC12 cells was significantly reduced by CuZn-PEP NZs. Meanwhile, CuZn-PEP NZs with multiple redox pairs exhibit superoxide dismutase, catalase, and glutathione peroxidase-mimicking enzyme properties simultaneously, which further display cytoprotective effects against Aβ fibril-induced reactive oxygen species and mitochondrial damage. Besides, cellular studies verified that CuZn-PEP NZs possess excellent biocompatibility and blood–brain barrier penetration capacity. Overall, these bimetallic-peptide framework nanozymes represent a promising perspective for attenuation of amyloid-β aggregation and reactive oxygen species simultaneously, which highlights the potential of nanozymes for the treatment of amyloidosis and reactive oxygen species-mediated AD progression.


  • A peptide-based conductive hydrogel capable of in situ bioelectrocatalytic NADH regeneration for sustained production of 1-propanol

    by Yaping Liu, Mingchen Lv, Ran Chen, Zhuo Zhang, Runxin Teng, Jinlong Qin, Min Sun, Zhen Fan, Jianzhong Du

    Nicotinamide-adenine dinucleotide (NAD+/NADH) is a coenzyme that acts as a donor and acceptor of electrons in redox reactions within all eukaryotic cells. The reduction of NAD+ produces NADH that subsequently acts as the key electron carrier. However, limited stability of enzymes under operational conditions, unwanted by-products and limited external electron donors result in low efficiency of NADH regeneration to drive the downstream enzymatic reactions. Herein, we modularly designed a peptide hydrogel, which provided an appropriate physiological microenvironment for maintaining the bioactivity of alcohol dehydrogenase. Meanwhile, Bi nanoparticles were in situ synthesized and doped into nanofibers during the peptide self-assembly to afford a conductive hydrogel with enhanced bioelectrocatalytic efficiency. Both linear sweep voltammetry and chronoamperometry data unveiled excellent electrochemical performance of this hydrogel for sustained NADH regeneration at low potential (−0.37 V vs. RHE). Even at a relatively high potential of −0.79 V vs. RHE, the yield of NADH for 10 h was as high as 81%. The regenerated NADH could further drive propionaldehyde alcoholization to produce 1-propanol sustainably with a rate of 1.34 mM h−1 at −0.62 V (vs. RHE). Overall, this peptide-based conductive hydrogel could achieve sustained 1-propanol production by leveraging in situ bioelectrocatalytic NADH regeneration, demonstrating a promising approach for electroenzymatic biofuel and pharmaceutical production.